Summary

KEY FINDINGS
The Europe 3D bioprinting market is predicted to register a CAGR of 16.64% during the forecast period, 2023-2032. The surging demand for advanced therapies across multiple segments is expected to drive the demand for bioprinting techniques across the region. In addition, the European Union (EU) has identified bioprinting as an advanced technology that will propel the development of future pharmaceutical and medical products and services.
MARKET INSIGHTS
France, Nordic Countries, Spain, Germany, the United Kingdom, Italy, and Rest of Europe are analyzed for the Europe 3D bioprinting market growth assessment. Germany offers significant growth opportunities and is the largest bioprinting market in Europe. The adoption of bioprinting solutions during the pandemic has opened up new avenues for technology in the country. Also, the rising incidences of chronic diseases like heart issues and kidney failures, the growing aging population, and a limited number of organ donors are projected to contribute to market growth. For instance, there will by 24 billion people aged 65 or above by 2035.
Additionally, there is a great disparity between organ donations and organ demand in the country. As per the German Organ Transplantation Foundation, 3,508 organs were transplanted in Germany in 2021. Of these, 529 were living donor transplants. Further, in countries like Sweden, researchers at the Sahlgrenska Academy and the Chalmers University of Technology used 3D bioprinting to induce living human cartilage cells in an animal. Such factors boost the market growth in these countries.
COMPETITIVE INSIGHTS
Some of the prominent firms in the market include Inventia Life Science Pty Ltd, EnvisionTEC M Inc, GeSiM GmbH, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON 3D BIOPRINTING MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. EMERGENCE OF 4D BIOPRINTING AS A SUBSTITUTE FOR 3D BIOPRINTING
2.5.2. PERSONALIZED MEDICINE LIKELY TO BOOST 3D BIOPRINTING
2.5.3. RISING INTEREST IN THE APPLICATION OF BIOPRINTING AGAINST THE SARS-COV-2 VIRUS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGING GERIATRIC POPULATION
3.1.2. TECHNOLOGICAL ADVANCEMENTS AND R&D INVESTMENTS
3.1.3. RISING FOCUS ON REGENERATIVE MEDICINE
3.1.4. HIGH PREVALENCE OF CHRONIC CONDITIONS
3.2. KEY RESTRAINTS
3.2.1. OPERATIONAL CHALLENGES DURING MANUFACTURING
3.2.2. EXORBITANT COSTS OF 3D BIOPRINTERS
3.2.3. LACK OF TRAINED PROFESSIONALS
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING IN GERMANY
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. DESIGN & SOFTWARE PROVIDERS
4.7.2. PROTOTYPE PRODUCTION
4.7.3. DISTRIBUTION
4.7.4. END-USERS
5. MARKET BY COMPONENT
5.1. 3D BIOPRINTER
5.2. BIOINK
6. MARKET BY BIOMATERIAL
6.1. HYDROGEL
6.2. LIVING CELLS
6.3. EXTRACELLULAR MATRICES
6.4. OTHER BIOMATERIALS
7. MARKET BY TECHNOLOGY
7.1. MAGNETIC LEVITATION BIOPRINTING
7.2. INKJET-BASED BIOPRINTING
7.3. SYRINGE/EXTRUSION-BASED BIOPRINTING
7.4. LASER-ASSISTED BIOPRINTING
7.5. OTHER TECHNOLOGIES
8. MARKET BY APPLICATION
8.1. DRUG TESTING & DEVELOPMENT
8.2. TISSUE ENGINEERING & REGENERATIVE MEDICINE
8.3. FOOD TESTING
8.4. RESEARCH
8.5. OTHER APPLICATIONS
9. MARKET BY END-USER
9.1. HOSPITALS
9.2. BIOPHARMACEUTICALS COMPANIES
9.3. RESEARCH ORGANIZATIONS AND ACADEMIC INSTITUTES
9.4. OTHER END-USERS
10. GEOGRAPHICAL ANALYSIS
10.1. EUROPE
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. EUROPE 3D BIOPRINTING MARKET DRIVERS
10.1.3. EUROPE 3D BIOPRINTING MARKET CHALLENGES
10.1.4. EUROPE 3D BIOPRINTING MARKET REGULATORY FRAMEWORK
10.1.5. KEY PLAYERS IN EUROPE 3D BIOPRINTING MARKET
10.1.6. COUNTRY ANALYSIS
10.1.6.1. UNITED KINGDOM
10.1.6.1.1. UNITED KINGDOM 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.2. GERMANY
10.1.6.2.1. GERMANY 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.3. FRANCE
10.1.6.3.1. FRANCE 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.4. ITALY
10.1.6.4.1. ITALY 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.5. SPAIN
10.1.6.5.1. SPAIN 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.6. NORDIC COUNTRIES
10.1.6.6.1. NORDIC COUNTRIES 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.7. REST OF EUROPE
10.1.6.7.1. REST OF EUROPE 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
11.2.1. 3D BIOPRINTING SOLUTIONS
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCTS LIST
11.2.2. ADVANCED SOLUTIONS LIFE SCIENCES
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCTS LIST
11.2.3. ALLEVI
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCTS LIST
11.2.4. CELLINK
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCTS LIST
11.2.4.3. STRENGTHS & CHALLENGES
11.2.5. COLLPLANT BIOTECHNOLOGIES LTD
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCTS LIST
11.2.6. CYFUSE BIOMEDICAL KK
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCTS LIST
11.2.6.3. STRENGTHS & CHALLENGES
11.2.7. ENVISIONTEC ṁ INC
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCTS LIST
11.2.7.3. STRENGTHS & CHALLENGES
11.2.8. GESIM GMBH
11.2.8.1. COMPANY OVERVIEW
11.2.8.2. PRODUCTS LIST
11.2.8.3. STRENGTHS & CHALLENGES
11.2.9. INVENTIA LIFE SCIENCE PTY LTD
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCTS LIST
11.2.10. ORGANOVO HOLDINGS INC
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCTS LIST
11.2.10.3. STRENGTHS & CHALLENGES
11.2.11. REGEMAT 3D
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCTS LIST
11.2.11.3. STRENGTHS & CHALLENGES
11.2.12. REGENHU
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCTS LIST
11.2.12.3. STRENGTHS & CHALLENGES
11.2.13. REVOTEK CO LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCTS LIST
11.2.14. ROKIT HEALTHCARE INC
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS LIST
11.2.15. STRATASYS LTD
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCTS LIST